Rethinking nonadherence: Historical perspectives on triple-drug therapy for HIV disease

Annals of Internal Medicine

Volumn 129, Issue 7, 1998, Pages 573-578

  Lerner, Barron H ^a   Gulick, Roy M ^b   Dubler, Nancy Neveloff ^c  

^a Box 11 ^*  (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCTOR PATIENT RELATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT RIGHT; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

EID: 0032190338     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-129-7-199810010-00012     Document Type: Review

References (92)

1. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA. 1998;280: 35-41.
2. Sontag D, Richardson L. Doctors withhold HIV pill regimen from some. New York Times. 2 March 1997:A1.
3. Chesney MA. Compliance: how you can help. HIV Newsline. 1997;3:67-72.
4. Senak M. Predicting antiviral compliance: physicians' responsibilities vs. patients' rights. Journal of the International Association of Physicians in AIDS Care. 1997;3:45-8.
5. Bangsberg D, Tulsky JP, Hecht FM, Moss AR. Protease inhibitors in the homeless. JAMA. 1997;278:63-5.
6. Crespo-Fierro M. Compliance/adherence and care management in HIV disease. J Assoc Nurses AIDS Care. 1997;8:43-54.
7. Mehta S, Moore RD, Graham NM. Potential factors affecting adherence with HIV therapy [Editorial]. AIDS. 1997;11:1665-70.
8. Eldred L, Gallant JE. Antiretroviral medication compliance: adherence in the era of triple-drug regimens. Northwestern University Reports on HIV/AIDS. 1998;2:1-3, 7-8.
9. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA. 1998;279:1977-83.
10. Winslow CE. The Life of Hermann Biggs, M.D., D.Sc., LL.D.: Physician and Statesman of the Public Health. Philadelphia: Lea & Febiger; 1929:131-52.
11. Teller ME. The Tuberculosis Movement: A Public Health Campaign in the Progressive Era. New York: Greenwood Pr; 1988:93-4.
12. Biggs HM. The administrative control of tuberculosis. Medical News. 1904; 84:337-45.
13. Foster JP. Detention institutes for ignorant and vicious consumptives. Transaction of the National Association for the Study and Prevention of Tuberculosis. 1905;1:333-8.
14. Rothman SM. Seek and hide: public health departments and persons with tuberculosis, 1890-1940. J Law Med Ethics. 1993;21:289-95.
15. Lerner BH. Temporarily detained: tuberculous alcoholics in Seattle, 1949 through 1960. Am J Public Health. 1996;86:257-65.
16. Lerner BH. Contagion and Confinement: Controlling Tuberculosis along the Skid Road. Baltimore, MD: Johns Hopkins Univ Pr; 1998.
17. Bridge E. The recalcitrant patient. Bulletin of the National Tuberculosis Association. 1949;35:119-20.
18. Northrop C. The practical management of the recalcitrant tuberculous patient. Public Health Rep 1952;67:894-8.
19. Davies R. Isolating the recalcitrants. Bull Nat Tuberc Assoc. 1954;40:121-2.
20. Webster's Third New International Dictionary of the English Language, Unabridged. Springfield, MA: Merriam-Webster; 1981.
21. Kahn MA. Tuberculosis: behind the scene [Letter]. N Engl J Med. 1977;297:1294-5.
22. Mitchell RS. Control of tuberculosis. N Engl J Med. 1967;276:905-11.
23. Pragoff H. Adjustment of tuberculosis patients one year after discharge. Public Health Rep. 1962;77:671-9.
24. Trostle JA. Medical compliance as an ideology. Soc Sci Med. 1988;27:1299-308.
25. Mohler DN, Wallin DJ, Dreyfus EG. Studies in the home treatment of streptococcal disease. I. Failure of patients to take penicillin by mouth as prescribed. N Engl J Med. 1955;252:1116-8.
26. Bergman AB, Werner RJ. Failure of children to receive penicillin by mouth. N Engl J Med. 1963;268:1334-8.
27. Charney E, Bynum R, Eldredge D, Frank D, MacWhinney JB, McNabb N, et al. How well do patients take oral penicillin? A collaborative study in private practice. Pediatrics. 1967;40:188-95.
28. Sackett DL, Haynes RB, eds. Compliance with Therapeutic Regimens. Baltimore, MD: Johns Hopkins Univ Pr; 1976.
29. Haynes RB, Taylor DW, Sackett DL, eds. Compliance in Health Care. Baltimore, MD: Johns Hopkins Univ Pr, 1979.
30. Davis MS, Eichhorn RL. Compliance with medical regimens: a panel study. J Health Hum Behav. 1963;54:240-9.
31. Becker MH, Maiman LA. Sociobehavioral determinants of compliance with health and medical care recommendations. Med Care. 1975;13:10-24.
32. Rosenstock I. Patients' compliance with health regimens. JAMA. 1975;234: 402-3.
33. Probstfield JL. Clinical trial prerandomization compliance (adherence) screen. In: Cramer JA, Spilker B, eds. Patient Compliance in Medical Practice and Clinical Trials. New York: Raven Pr; 1991:323-33.
34. Haynes RB, Wang E, Gomes MD. A critical review of interventions to improve compliance with prescribed medications. Patient Education and Counseling. 1987;10:155-66.
35. Bond WS, Hussar DA. Detection methods and strategies for improving medication compliance. Am J Hosp Pharm. 1991;48:1978-88.
36. Sumartojo E. When tuberculosis treatment fails. A social behavioral account of patient adherence. Am Rev Respir Dis. 1993;147:1311-20.
37. DiMatteo MR. Enhancing patient adherence to medical recommendations. JAMA. 1994;271:79, 83.
38. Roter DL, Hall JA. Strategies for enhancing patient adherence to medical recommendations. JAMA. 1994;271:80.
39. Sbarbaro JA, Sbarbaro JB. Compliance and supervision of chemotherapy of tuberculosis. Semin Respir Infect. 1994;9:120-7.
40. Haynes RB, McKibbon KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet. 1996;348:383-6.
41. Eraker SA, Kirscht JP, Becker MH. Understanding and improving patient compliance. Ann Intern Med. 1984;100:258-68.
42. Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G. Is this patient taking the treatment as prescribed? JAMA. 1993;269:2779-81.
43. Rudd P, Byyny RL, Zachary V, LoVerde ME, Titus C, Mitchell WD, et al. The natural history of medication compliance in a drug trial: limitations of pill counts. Clin Pharmacol Ther. 1989;46:169-76.
44. Urquhart J. Ascertaining how much compliance is enough with outpatient antibiotic regimens. Postgrad Med J. 1992;68(Suppl 3):S49-S58.
45. Sackett DL, Haynes RB, Gibson ES, Hackett BC, Taylor DW, Roberts RS, et al. Randomised clinical trial of strategies for improving medication compliance in primary hypertension. Lancet. 1975;1:1205-7.
46. Brudney K, Dobkin J. Resurgent tuberculosis in New York City. Human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. Am Rev Respir Dis. 1991;144:745-9.
47. el-Sadr W, Medard F, Berthaud V. Directly observed therapy for tuberculosis: the Harlem Hospital experience, 1993. Am J Public Health. 1996;86(8 pt 1):1146-9.
48. Pablos-Mendez A, Knirsch CA, Barr RG, Lerner BH, Frieden TR. Non-adherence in tuberculosis treatment: predictors and consequences in New York City. Am J Med. 1997;102:164-70.
49. Davis MS. Predicting non-compliant behavior. J Health Soc Behav. 1967;8: 265-71.
50. Mushlin AI, Appel FA. Diagnosing potential noncompliance. Physicians' ability in a behavioral dimension of medical care. Arch Intern Med. 1977;137: 318-21.
51. Norell SE. Accuracy of patient interviews and estimates by clinical staff in determining medication compliance. Soc Sci Med. 1981;15:57-61.
52. Samet JH, Libman H, Steger KA, Dhawan RK, Chen J, Shevitz AH, et al. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med. 1992;92:495-502.
53. Freeman RC, Rodriguez GM, French JF. Compliance with AZT treatment regimen of HIV-seropositive injection drug users: a neglected issue. AIDS Educ Prev. 1996;8:58-71.
54. Eldred U, Wu AW, Chaisson RE, Moore RD. Adherence to antiretroviral therapy in HIV disease [Abstract]. Programs and Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections, 22-26 January 1997, Washington, DC.
55. Cowan FM, Jones G, Bingham J, Flegg PJ, MacCallum LR, Whitelaw J, et al. Use of zidovudine for drug misusers infected with human immunodeficiency virus. J Infect. 1989;18(Suppl 1):59-66.
56. Samuels JE, Hendrix J, Hilton M, Marantz PR, Sloan V, Small CB. Zidovudine therapy in an inner city population. J Acquir Immune Defic Syndr. 1990;3:877-83.
57. Broers B, Morabia A, Hirschel B. A cohort study of drug users' compliance with zidovudine treatment. Arch Intern Med. 1994;154:1121-7.
58. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA. 1997;277:145-53.
59. McDonald CK, Kuritzkes DR. Human immunodeficiency virus type 1 protease inhibitors. Arch Intern Med. 1997;157:951-9.
60. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med. 1993;328:521-6.
61. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med. 1995;333:1528-33.
62. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med. 1995;333:1534-9.
63. Vanhove GF, Schapiro JM, Winters MA, Merigan TC, Blaschke TF. Patient compliance and drug failure in protease inhibitor monotherapy [Letter]. JAMA. 1996;276:1955-6.
64. Montouh L, Corbeil J, Richman DD. Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure. Proc Natl Acad Sci U S A. 1996;93:6106-11.
65. Mellors J. Viral determinants of HIV disease progression. Programs and Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections, 22-26 January 1997, Washington, DC.
66. Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, et al. A randomized, double-blind trial comparing combinations of nevaripine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. Italy, The Netherlands, Canada and Australia Study. JAMA. 1998;279:930-7.
67. Improving Patient Adherence to Tuberculosis Treatment. Atlanta, GA: Centers for Disease Control and Prevention; 1994:19-37.
68. Williford SL, Johnson DF. Impact of pharmacist counseling on medication knowledge and compliance. Mil Med. 1995;160:561-4.
69. Milch RA, Ziv L, Evans V, Hillebrand M. The effect of alphanumeric paging system on patient compliance with medicinal regimens. Am J Hosp Palliat Care. 1996;13:46-8.
70. Miller NH, Hill M, Kottke T, Ockene IS. The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals. Circulation. 1997;95:1085-90.
71. Ickovics JR, Meisler AW. Adherence in AIDS clinical trials: a framework for clinical research and clinical care. J Clin Epidemiol. 1997;50:385-91.
72. Donovan JL. Patient decision making. The missing ingredient in compliance research, Int J Technol Assess Health Care. 1995;11:443-55.
73. Lerner BH. From careless consumptives to recalcitrant patients: the historical construction of noncompliance. Soc Sci Med. 1997;45:1423-31.
74. Slutkin G. Management of tuberculosis in urban homeless indigents. Public Health Rep. 1986;101:481-5.
75. Curtis R, Friedman SR, Neaigus A, Jose B, Goldstein M, Des Jarlais DC. Implications of directly observed therapy in tuberculosis control measures among IDUs. Public Health Rep. 1994;109:319-27.
76. Pilote L, Tulsky JP, Zolopa AR, Hahn JA, Schecter GF, Moss AR. Tuberculosis prophylaxis in the homeless. A trial to improve adherence to referral. Arch Intern Med. 1996;156:161-5.
77. Rubel AJ, Garro LC. Social and cultural factors in the successful control of tuberculosis. Public Health Rep. 1992;107:626-36.
78. Hughes JR. Exclusion of "noncompliant" individuals from clinical trials [Letter]. Control Clin Trials. 1993;14:176-7.
79. Treatment Adherence for People with HIV Infection: A Guide for Health Care Providers. Albany, NY: AIDS Institute, New York State Department of Health; 1998.
80. Greenfield S, Kaplan S, Ware JE Jr. Expanding patient involvement in care: effects on patient outcomes. Ann Intern Med. 1985;102:520-8.
81. Frank E, Kupfer DJ, Siegel LR. Alliance not compliance: a philosophy of outpatient care. J Clin Psychiatry. 1995;56(Suppl 1):11-6.
82. Blackwell B. From compliance to alliance. A quarter century of research. Neth J Med. 1996;48:140-9.
83. Kyngas H, Hentinen M, Koivukangas P, Ohinmaa A. Young diabetics' compliance in the framework of the MIMIC model. J Adv Nurs. 1996;24:997-1005.
84. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society - USA panel. JAMA. 1997;277:1962-9.
85. Saag MS, Holodniy M, Kuritzkes DR, O'Brien WA, Coombs R, Poscher ME, et al. HIV viral load markers in clinical practice. Nat Med. 1996;2:625-9.
86. Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society -USA panel. JAMA. 1998;279:1984-91.
87. Hudson LD, Sbarbaro JA. Twice weekly tuberculosis chemotherapy. JAMA. 1973;223:139-43.
88. Iseman MD, Cohn DL, Sbarbaro JA. Directly observed treatment of tuberculosis. We can't afford not to try it. N Engl J Med. 1993;328:576-8.
89. Voelker R. "Shoe leather therapy" is gaining on TB [News]. JAMA. 1996; 275:743-4.
90. Epstein S. Impure Science: AIDS, Activism, and the Politics of Knowledge. Berkeley, CA: Univ of California Pr; 1996.
91. Strategies to establish and maintain optimal adherence. HIV Newsline. 1997; 3:65-6.
92. Altman LK. Troubling side effects are linked to effective AIDS drug therapy. New York Times. 7 July 1998.F7.